METHODS
Consecutive patients who received the combination of an S-ICD (Boston Scientific, Marlborough, Massachusetts, USA ) and an AAE (TYRXTM, Medtronic, Minneapolis, Minnesota, USA ) between March 2018 and May 2020 were included in this study. The inclusion period was set from the time of the first “combined” procedure (S-ICD+AAE, March 2018) to May 2020, in order to include only patients with at least 12 months of follow-up. Patients were enrolled from the ELISIR project (Experience from the Long-term Italian S-ICD registry; ClinicalTrials.gov Identifier NCT0473876), which is a multi-center, open-label, independent, and physician-initiated observational registry, whose characteristics and preliminary composition have been previously described5. This analysis has been approved by the institutional review board, and has been drafted in accordance with the tenets of the Helsinki Declaration.